Brokerages Set Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Price Target at $7.40

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) has earned a consensus recommendation of “Moderate Buy” from the five ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $7.40.

Several research analysts have issued reports on the company. StockNews.com lowered Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 11th. HC Wainwright restated a “buy” rating and set a $4.00 price objective on shares of Actinium Pharmaceuticals in a report on Friday, November 15th. Finally, Stephens reaffirmed an “overweight” rating and issued a $5.00 price objective on shares of Actinium Pharmaceuticals in a research report on Tuesday, November 19th.

Actinium Pharmaceuticals Trading Down 2.6 %

ATNM opened at $1.33 on Friday. The stock has a 50-day moving average of $1.64. Actinium Pharmaceuticals has a 12 month low of $1.19 and a 12 month high of $10.24. The stock has a market capitalization of $41.33 million, a price-to-earnings ratio of -0.95 and a beta of 0.07.

Institutional Trading of Actinium Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in ATNM. Vanguard Group Inc. increased its stake in shares of Actinium Pharmaceuticals by 6.0% during the first quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock worth $11,325,000 after purchasing an additional 82,113 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Actinium Pharmaceuticals by 28.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock worth $639,000 after buying an additional 19,035 shares in the last quarter. Rhumbline Advisers increased its stake in Actinium Pharmaceuticals by 23.4% during the 2nd quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock worth $293,000 after buying an additional 7,525 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of Actinium Pharmaceuticals during the second quarter valued at approximately $142,000. Finally, Marshall Wace LLP lifted its position in shares of Actinium Pharmaceuticals by 67.9% in the second quarter. Marshall Wace LLP now owns 256,026 shares of the company’s stock valued at $1,895,000 after acquiring an additional 103,557 shares in the last quarter. 27.50% of the stock is currently owned by hedge funds and other institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).